Reports Q4 revenue $412.5M, consensus $371.3M. "As I reflect on the past year as Zymeworks’ new Chair and CEO, we made significant progress across all aspects of our business to reset the Company and its R&D strategy on a new path forward to building a successful biotechnology company. We recently outlined our enterprise value framework where we will continue to focus on advancing the business across the five pillars during 2023: our two zanidatamab collaborations with BeiGene and Jazz, our early research and development programs, zanidatamab zovodotin, and our legacy platform licensing portfolio," said Kenneth Galbraith, Chair and CEO of Zymeworks. "With the transformative nature of the completed collaboration with Jazz, we believe we are well positioned to advance all elements of our business during 2023 despite current challenging macroeconomic conditions, with a significantly reduced cash operating burn and expected cash runway extending through 2026."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZYME:
- Zymeworks shareholder EcoR1 Capital buys $3.0M in company shares
- Zymeworks price target raised to $16 from $15 at Guggenheim
- Jazz Pharmaceuticals, Zymeworks report 84% survival for zanidatamab in mGEA
- This Insider Just Spiked Investors’ Interest in Zymeworks (NASDAQ:ZYME) Stock
- Zymeworks up 4% afterhours as holder EcoR1 Capital buys $9.7M in common stock
